Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nuvo’s Pennsaid Resubmission Delayed Again

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm now projects a potential mid-2009 approval for the topical NSAID for osteoarthritis.

You may also be interested in...



R&D IN BRIEF

Pfizer halts Phase III axitinib trial: Pfizer announces the halt of Phase III axitinib trial in advanced pancreatic cancer patients late on Friday, Jan. 30. The press release was overshadowed by the news just days earlier of Pfizer's offer to merge with Wyeth (1"The Pink Sheet," Feb. 2, 2009, p. 8). The pancreatic trial evaluating axitinib - Pfizer's most advanced oncology candidate - was stopped after a data safety monitoring board found no evidence in interim results of improvement in the primary endpoint of survival in patients treated with axitinib and gemcitabine compared to gemcitabine alone (the current standard of care). Pfizer had predicted last summer that it would first file axitinib for pancreatic cancer (2"The Pink Sheet," June 23, 2008, p. 30); the firm is still committed to evaluating the VEGF receptor inhibitor in a Phase III second-line renal cell carcinoma trial and Phase II advanced non-small cell lung cancer and colorectal cancer studies

R&D IN BRIEF

Pfizer halts Phase III axitinib trial: Pfizer announces the halt of Phase III axitinib trial in advanced pancreatic cancer patients late on Friday, Jan. 30. The press release was overshadowed by the news just days earlier of Pfizer's offer to merge with Wyeth (1"The Pink Sheet," Feb. 2, 2009, p. 8). The pancreatic trial evaluating axitinib - Pfizer's most advanced oncology candidate - was stopped after a data safety monitoring board found no evidence in interim results of improvement in the primary endpoint of survival in patients treated with axitinib and gemcitabine compared to gemcitabine alone (the current standard of care). Pfizer had predicted last summer that it would first file axitinib for pancreatic cancer (2"The Pink Sheet," June 23, 2008, p. 30); the firm is still committed to evaluating the VEGF receptor inhibitor in a Phase III second-line renal cell carcinoma trial and Phase II advanced non-small cell lung cancer and colorectal cancer studies

Nuvo's Pennsaid “Approvable” For Osteoarthritis

Company plans to meet with FDA in early 2007 to discuss the topical non-steroidal anti-inflammatory treatment.

Related Content

Topics

UsernamePublicRestriction

Register

PS066201

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel